May 7, 2010 — The US Food and Drug Administration (FDA) has issued new dosing guidelines for colchicine (Colcrys tablets; URL Pharma, Inc) when used with protease inhibitors in HIV patients. According ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

The recent US approval of a new low dose of colchicine 0.5 mg (Lodoco; Agepha Pharma) with a broad indication for use in atherosclerotic cardiovascular disease (ASCVD) represents a completely new ...

URL Pharma, Inc., today announced that the FDA has issued new label information affecting all approved protease inhibitors for treatment of HIV when co-administered with Colcrys (colchicine). These ...

Scilex Holding Company announced the publication of important dosing adjustments for GLOPERBA®, its liquid oral colchicine product for gout management, in a peer-reviewed journal. GLOPERBA® is unique ...

Please provide your email address to receive an email when new articles are posted on . A 0.5 mg dose of colchicine has been approved for use in high-risk patients who have inflammatory risk. The dose ...

The media reports that colchicine, a very old drug, has now been discovered to reduce the risk of recurrent heart disease and has a new FDA indication. Of course, the “discovery” has taken 10 years, ...